Overview

A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D)

Status:
Completed

Trial end date:
2021-10-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and tolerability of different doses of AG019 administered alone or in combination with teplizumab in participants who recently developed Type 1 Diabetes Mellitus (T1D).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Intrexon T1D Partners, LLC
Precigen Actobio T1D, LLC

Collaborators:

ActoBio Therapeutics
Intrexon Actobiotics NV, d/b/a Precigen Actobio
TFS Trial Form Support